STOCK TITAN

ENDRA Life Sciences Q3 cash use rises to $1.8M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

ENDRA Life Sciences Inc. reported a third-quarter 2026 net loss of $1,528,528, versus $1,595,959 a year earlier, while cash used in operations rose to $1.8 million from $1.2 million. Operating expenses were $1,715,163 versus $1,370,703; research and development expense was approximately $176,000 versus $432,000, while general and administrative expense was $1.5 million versus $893,000. Net other income was $186,635, compared with net other expense of $225,256. Nine-month net loss was $2,680,017 versus $3,858,201.

As of September 30, 2026, ENDRA had $1,516,523 in unrestricted cash, $3,425,003 in restricted cash tied to its May 2026 financing and related contractual obligations, and $1,261,490 in digital assets. ENDRA is advancing a proposed merger with Noble Africa LLC, an ASP Isotopes Inc. subsidiary; upon completion, Noble Africa would become ENDRA's wholly owned subsidiary and ENDRA would be renamed 4K Resources Inc. A concurrent private placement into Noble Africa is expected to produce approximately $50 million in gross proceeds. Closing remains subject to customary conditions, including ENDRA stockholder approval, effectiveness of the Form S-4 registration statement and compliance with applicable Nasdaq listing requirements. ENDRA continued developing its third-generation ultrasound product.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointNine-month net loss declined to $2,680,017 from $3,858,201.

Negative

  • Moderate pointQuarterly operating cash use rose to $1.8 million from $1.2 million.

Filing Explained

The third-quarter balance sheet reports ENDRA had 1,499,838 common shares outstanding at September 30, 2026, versus 1,176,477 at December 31, 2025; the higher share count means an existing holder’s ownership percentage is lower, absent offsetting changes.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net loss $1,528,528 Three months ended September 30, 2026; $1,595,959 in the comparable 2025 period
Cash used in operations $1.8 million Third quarter 2026; $1.2 million in the same period of 2025
Operating expenses $1,715,163 Three months ended September 30, 2026; $1,370,703 in the comparable 2025 period
Nine-month net loss $2,680,017 Nine months ended September 30, 2026; $3,858,201 in the comparable 2025 period
Unrestricted cash $1,516,523 As of September 30, 2026
Restricted cash $3,425,003 As of September 30, 2026; relates to the May 2026 financing and associated contractual obligations
Digital assets $1,261,490 As of September 30, 2026
Expected gross proceeds Approximately $50 million Expected from the proposed concurrent private placement into Noble Africa
thermoacoustic biomarker imaging technical
"pioneer in thermoacoustic biomarker imaging for early detection"
Thermoacoustic biomarker imaging is a noninvasive medical imaging method that uses short electromagnetic pulses to gently heat tissues so they produce tiny sound waves, which are then recorded to create maps of specific biological signals or contrast agents. Investors care because it promises a new way to detect disease markers or monitor therapy without radiation or large scans—potentially creating markets for new devices, diagnostic contrast agents, and clinical services if adopted widely.
Thermo Acoustic Enhanced UltraSound (TAEUS®) technical
"pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®)"
steatotic liver disease medical
"monitoring of steatotic liver disease"
Steatotic liver disease is a condition where excess fat builds up in the liver, like a filter becoming clogged with grease, which can impair the organ’s normal functions. It matters to investors because rising prevalence can drive demand for drugs, diagnostics and medical services, raise healthcare and insurance costs, and affect workforce productivity and regulatory scrutiny—factors that influence valuations and revenues across healthcare and related industries.
metabolic dysfunction-associated steatohepatitis medical
"steatotic liver disease and metabolic dysfunction-associated steatohepatitis"
Metabolic dysfunction-associated steatohepatitis is a liver disease in which fat buildup tied to metabolic problems such as obesity and diabetes leads to inflammation and scarring, like rust forming inside a machine that gradually impairs function. It matters to investors because its growing prevalence creates large markets for drugs, diagnostics and care, and clinical trial results, approvals, or reimbursement decisions can sharply change the value of healthcare companies working in this area.
digital asset staking compensation financial
"Digital asset staking compensation"
warrant liability financial
"Changes in fair value of warrant liability"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
Net loss $1,528,528 Compared with $1,595,959 in the third quarter of 2025
Cash used in operations $1.8 million Compared with $1.2 million in the same period of 2025
Operating expenses $1,715,163 Compared with $1,370,703 in the same period of 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were NDRA’s third-quarter 2026 net loss and operating cash use?

NDRA reported a net loss of $1,528,528 and cash used in operations of $1.8 million for the three months ended September 30, 2026. The comparable 2025 figures were a $1,595,959 net loss and $1.2 million of operating cash use.

When is the NDRA-Noble Africa private placement expected to close?

The concurrent private placement into Noble Africa is expected to close immediately before the merger and the contribution of ASP Isotopes’ ownership interest in Renergen to Noble Africa.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001681682 0001681682 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 16, 2026

 

ENDRA Life Sciences Inc. 
(Exact name of registrant as specified in its charter)

 

Delaware   001-37969   26-0579295
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

3600 Green Court, Suite 350 Ann Arbor, MI   48105
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code   (734) 335-0468

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☒Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   NDRA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition

 

On November 16, 2026, ENDRA Life Sciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated November 16, 2026, furnished herewith.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENDRA Life Sciences Inc.
November 16, 2026  
  By: /s/ Richard Jacroux
  Name:  Richard Jacroux
  Title: Chief Financial Officer

 

2

 

Exhibit 99.1

 

November 16, 2026

 

ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update

 

ANN ARBOR, Mich. (November 16, 2026) – ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

 

Business Update

 

During the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product. At the same time, ENDRA is working to advance its proposed merger with Noble Africa LLC (“Noble Africa”), a subsidiary of ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”), and managed its operating resources in anticipation of the proposed transaction.

 

Pursuant to the merger agreement announced on June 25, 2026, Noble Africa will become a wholly owned subsidiary of ENDRA, and ENDRA will be renamed 4K Resources Inc. The proposed transaction includes a concurrent private placement into Noble Africa that is expected to result in total gross proceeds of approximately $50 million, and is expected to close immediately before the merger and the contribution of ASP Isotopes’ ownership interest in Renergen Limited (“Renergen”) to Noble Africa.

 

Completion of the transaction remains subject to customary closing conditions, including stockholder approvals, effectiveness of the registration statement on Form S-4, and compliance with applicable Nasdaq listing requirements.

 

Management Commentary

 

“Our focus during the third quarter remained on completing the proposed merger with Noble Africa while managing ENDRA’s operating resources and liquidity to support transaction-related priorities,” said Alexander Tokman, Chairman and Chief Executive Officer of ENDRA Life Sciences.

 

“The proposed transaction represents an important strategic opportunity for our stockholders. We continue to work with our merger counterparties to complete the remaining steps necessary to close the merger.”

 

 

 

Third Quarter 2026 Financial Results

 

Cash used in operations during the third quarter of 2026 was $1.8 million, compared with $1.2 million in the same period of 2025, primarily reflecting higher professional fees associated with the proposed merger, digital asset management, and performance fees.

 

Operating expenses in the third quarter of 2026 were $1.7 million, compared with $1.4 million in the same period of 2025. Research and development expenses declined to approximately $176,000 from $432,000 in the comparable prior-year period, while general and administrative expenses increased to $1.5 million from $893,000 in the prior-year period, primarily reflecting higher professional fees and costs associated with the Company’s merger-related activities.

 

The net loss for the third quarter of 2026 was $1.5 million, compared with a net loss of $1.6 million in the third quarter of 2025. The improvement in net loss reflected approximately $187,000 of net other income in the third quarter of 2026, compared with approximately $225,000 of net other expense in the prior-year period.

 

As of September 30, 2026, ENDRA had $1.5 million in unrestricted cash, $3.4 million in restricted cash, and $1.3 million in digital assets. The restricted cash relates to the Company’s May 2026 financing and associated contractual obligations.

 

About ENDRA Life Sciences Inc.

 

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.

 

Important Additional Information and Where to Find It

 

This press release relates to the proposed merger and related transactions (the “Proposed Transactions”) involving ENDRA, ASP Isotopes, Renergen and Noble Africa, and may be deemed to be solicitation material in respect of the Proposed Transactions. In connection with the Proposed Transactions, ENDRA has filed relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that contains a proxy statement (the “Proxy Statement”) and prospectus. This press release is not a substitute for the Form S-4, the Proxy Statement or for any other document that ENDRA may file with the SEC and/or send to its stockholders in connection with the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP ISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.

 

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by ENDRA and ASP Isotopes with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. ENDRA’s Internet website address is www.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through the investor relations page of its Internet website as soon as reasonably practicable after it electronically files such material with, or furnishes such material to, the SEC.

 

2

 

Participants in the Solicitation

 

ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from ENDRA’s stockholders in connection with the Proposed Transactions under the rules of the SEC. Information about ENDRA’s directors and executive officers, including a description of their interests in ENDRA, is included in ENDRA’s most recent Annual Report on Form 10-K for the year ended December 31, 2025. Information about ASP Isotopes’ directors and executive officers, including a description of their interests in ASP Isotopes, is included in ASP Isotopes’ most recent Annual Report on Form 10-K for the year ended December 31, 2025. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including the directors and executive officers of Renergen, and a description of their direct and indirect interests, by security holdings or otherwise, are also included in the Form S-4 and the Proxy Statement and may be included in other relevant materials filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

 

No Offer or Solicitation

 

This press release is not intended to and does not constitute a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transactions or an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

 

3

 

Forward-Looking Statements

 

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements—based on certain assumptions and describing our future plans, strategies, and expectations—can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “can,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are express differently. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

 

Applicable risks and uncertainties include, among others: the risk that the conditions to the closing or consummation of the proposed merger with Noble Africa and related transactions (the “Proposed Transactions”) are not satisfied, including the failure to timely obtain approval of the Proposed Transactions from ENDRA stockholders, if at all; the risk that the proposed financings are not completed in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of ENDRA and Noble Africa to consummate the Proposed Transactions; risks related to ENDRA’s continued listing on Nasdaq until closing of the Proposed Transactions and the combined company’s ability to remain listed following the closing of the Proposed Transactions; risks related to ENDRA’s ability to correctly estimate its operating expenses and its expenses associated with the Proposed Transactions, pending the closing of the Proposed Transactions, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of ENDRA, and other events and unanticipated spending and costs that could reduce ENDRA’s cash resources; risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the Proposed Transactions on ENDRA’s or Noble Africa’s business relationships, operating results and business generally; costs related to the Proposed Transactions; risks related to the market price of ENDRA’s common stock relative to the value suggested by the Proposed Transactions; the outcome of any legal proceedings that may be instituted against ENDRA, Noble Africa or any of their respective directors, managers, or officers related to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or expenses resulting from the Proposed Transactions; changes in regulatory requirements and government incentives; risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results, legislative, regulatory, political and economic developments, and those uncertainties and factors; and the risk of involvement in litigation, including securities class action litigation, that could divert the attention of the management of ENDRA or the combined company, harm the combined company’s business and may not be sufficient for insurance coverage to cover all costs and damages, expectations regarding our treasury strategy and our ability to execute it successfully; our limited commercial experience, limited cash resources, and history of losses; our ability to obtain adequate financing to fund operations in the future; our ability to regain and maintain compliance with Nasdaq listing standards; delays or changes in regulatory requirements, policies, or guidelines; the repeatability of clinical results across larger trial populations; potential delays in submitting required regulatory applications or other submissions to, or receiving approvals from, the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies; our ability to obtain and maintain required CE mark certifications and secured required FDA and other governmental approvals for our Thermo Acoustic Enhanced Ultrasound (“TAEUS®”) applications; our ability to develop commercially viable products based on our TAEUS® technology; market acceptance of our technology; the effect of macroeconomic conditions on our business; results of studies, which may be negative or inconclusive; our ability to secure and maintain development partners; reliance on third parties, collaborations, strategic alliances, and licensing arrangements; the competitive landscape in the healthcare industry; our ability to protect our intellectual property; changes in healthcare industry practices or reimbursement policies; our ability to comply with regulations from federal, state, local, and foreign governmental agencies; risks related to shifts in regulatory, accounting, or tax treatment affecting our treasury activities; the potential impact of any changes in financial reporting requirements; the risk that our stock price may be affected by the performance or valuation of assets held in our treasury; a determination that we are an investment company under the Investment Company Act of 1940; our ability to achieve profitability; our dependence on key members of management; and other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

 

You should not rely on forward-looking statements as predictions of future events. Forward-looking statements in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update such statements to reflect actual results or changes in expectations, except as required by law.

 

4

 

ENDRA Life Sciences Inc.

Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2026   2025 
Assets  (Unaudited)     
         
Current Assets        
Cash  $1,516,523   $762,365 
Restricted cash   3,425,003    - 
Prepaid expenses   109,590    205,604 
Total Current Assets   5,051,116    967,969 
Non-Current Assets          
Fixed assets, net   35,603    42,516 
Right of use assets   368,903    461,949 
Prepaid expenses, long term   -    365,417 
Digital Assets   1,261,490    2,009,960 
Other assets   5,986    5,986 
Total Assets  $6,723,098   $3,853,797 
           
Liabilities and Stockholders’ Equity          
Current Liabilities          
Accounts payable and accrued liabilities  $492,272   $621,578 
Lease liabilities, current portion   143,452    129,378 
Total Current Liabilities   635,724    750,956 
           
Long Term Liabilities          
Lease liabilities   253,085    362,974 
Warrant Liability   632,475    479,747 
Total Long Term Liabilities   885,560    842,721 
           
Total Liabilities   1,521,284    1,593,677 
Commitments and Contingencies   -    - 
           
Stockholders’ Equity          
Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 17.488 shares issued and outstanding, respectively   -    - 
Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding   -    - 
Series C Convertible Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 1,499,838 and 1,176,477 shares issued and outstanding, respectively   148    116 
Additional paid in capital   118,356,529    112,725,513 
Receivable related to employee equity awards   (9,337)   - 
Accumulated deficit   (113,145,526)   (110,465,509)
Total Stockholders’ Equity   5,201,814    2,260,120 
Total Liabilities and Stockholders’ Equity  $6,723,098   $3,853,797 

 

5

 

ENDRA Life Sciences Inc.

Condensed Consolidated Statement of Operations

(Unaudited)

 

   Three Months
Ended
   Three Months
Ended
   Nine Months
Ended
   Nine Months
Ended
 
   September 30,   September 30,   September 30,   September 30, 
   2026   2025   2026   2025 
Operating Expenses                
Research and development  $176,280   $432,113   $1,186,355   $1,341,859 
Sales and marketing   -    45,285    10,091    183,110 
General and administrative   1,538,883    893,305    4,175,721    2,616,106 
Total operating expenses   1,715,163    1,370,703    5,372,167    4,141,075 
                     
Operating loss   (1,715,163)   (1,370,703)   (5,372,167)   (4,141,075)
                     
Other Income (Expenses)                    
Other income (expense)   (28)   42,018    278    79,474 
Digital asset staking compensation   778    -    21,538    - 
Unrealized gain on change in fair value of digital assets   168,049    -    2,197,117    - 
Realized gain on change in fair value of digital assets   341,872    -    872,812    - 
Digital asset management and performance fees   (246,867)   -    (246,867)   - 
Changes in fair value of warrant liability   (77,169)   (267,274)   (152,728)   203,400 
Total other income/(expense)   186,635    (225,256)   2,692,150    282,874 
                     
Income/(loss) from operations before income taxes   (1,528,528)   (1,595,959)   (2,680,017)   (3,858,201)
                     
Provision for income taxes   -    -    -    - 
                     
Net Income (Loss)  $(1,528,528)  $(1,595,959)  $(2,680,017)  $(3,858,201)
                     
Net income (loss) per share – basic and diluted  $(1.02)  $(2.10)  $(2.00)  $(5.68)
                     
Weighted average common shares – basic and diluted   1,499,838    761,218    1,342,470    679,210 

 

Company Contact:
Investor Relations
investors@endrainc.com
www.endrainc.com

 

Investor Relations Contact:
Vivian Cervantes
Alliance Advisors IR
973-873-7724
vcervantes@allianceadvisors.com

 

6

 

Filing Exhibits & Attachments

4 documents

Keep reading